ArticleClinical and molecular hepatology2023
The current trends in the health burden of primary liver cancer across the globe.
Article in Clinical and molecular hepatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 21 citations in OpenAlex.
- Risk Prediction of Early-Onset Hepatocellular Carcinoma: Derivation and Validation in a Nationwide Young Adult Cohort.Alimentary pharmacology & therapeutics · 2026Article
- Integrative systems biology and transcriptomic database analysis (GEPIA2 and TNMplot) uncover HRAS-driven anticancer mechanisms of anthraquinones in liver cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Dual-mode fluorescence and UV-vis aptasensor for hepatocellular carcinoma detection using magnetic separation.Mikrochimica acta · 2026Article
- A bibliometric analysis of research trends and hotspots on recurrence after thermal ablation for hepatocellular carcinoma 2005-2025.Discover oncology · 2026Article
- Multi-omics identification of therapeutic targets of compound sappan decoction in hepatocellular carcinoma.Discover oncology · 2026Article
- Increased Cardiovascular and Cerebrovascular Events in Patients With Lean vs Non-lean MASLD: A Multicenter Analysis.Clinical and translational gastroenterology · 2026Article
- Economic evaluations of the primary prevention programs for viral hepatitis-related liver disease and liver cancer: a systematic literature review.Cost effectiveness and resource allocation : C/E · 2026Review
- Global burden of HBV-related liver disease: Primary liver cancer due to chronic HBV infection increased in over one-third of countries globally from 2000 to 2021.Hepatology (Baltimore, Md.) · 2025Article
- Article
- MicroRNA-372-3p impairs fatty acid metabolism in hepatocellular carcinoma cells by targetingBioImpacts : BI · 2025Article
- Contemporary awareness of viral hepatitis between 2012 and 2022 among Korean adults.Clinical and molecular hepatology · 2025Article
- Long-term outcomes and risk modifiers of metabolic dysfunction-associated steatotic liver disease between lean and non-lean populations.Clinical and molecular hepatology · 2025Review
- Multidisciplinary comprehensive treatment of massive hepatocellular carcinoma with hemorrhage: A case report and review of literature.World journal of gastrointestinal oncology · 2024Article
- Current epidemiology of chronic liver disease.Gastroenterology report · 2024Review
- Modulation of gut microbiota by probiotics to improve the efficacy of immunotherapy in hepatocellular carcinoma.Frontiers in immunology · 2024Review
Corrections and comments
- Comment on
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.